These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23990986)

  • 1. Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.
    Burford A; Little SE; Jury A; Popov S; Laxton R; Doey L; Al-Sarraj S; Jürgensmeier JM; Jones C
    PLoS One; 2013; 8(8):e71777. PubMed ID: 23990986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
    Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
    J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
    Puputti M; Tynninen O; Sihto H; Blom T; Mäenpää H; Isola J; Paetau A; Joensuu H; Nupponen NN
    Mol Cancer Res; 2006 Dec; 4(12):927-34. PubMed ID: 17189383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study.
    Nobusawa S; Stawski R; Kim YH; Nakazato Y; Ohgaki H
    Neuropathology; 2011 Dec; 31(6):583-8. PubMed ID: 21382095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.
    Jansson S; Bendahl PO; Grabau DA; Falck AK; Fernö M; Aaltonen K; Rydén L
    PLoS One; 2014; 9(7):e102176. PubMed ID: 25025175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDGFRA, KIT, and KDR Gene Amplification in Glioblastoma: Heterogeneity and Clinical Significance.
    Carlotto BS; Trevisan P; Provenzi VO; Soares FP; Rosa RFM; Varella-Garcia M; Zen PRG
    Neuromolecular Med; 2023 Sep; 25(3):441-450. PubMed ID: 37610648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis.
    Johansson I; Aaltonen KE; Ebbesson A; Grabau D; Wigerup C; Hedenfalk I; Rydén L
    Genes Chromosomes Cancer; 2012 Apr; 51(4):375-83. PubMed ID: 22170730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copy Number Profiling of Brazilian Astrocytomas.
    Bidinotto LT; Torrieri R; Mackay A; Almeida GC; Viana-Pereira M; Cruvinel-Carloni A; Spina ML; Campanella NC; Pereira de Menezes W; Clara CA; Becker AP; Jones C; Reis RM
    G3 (Bethesda); 2016 Jul; 6(7):1867-78. PubMed ID: 27172220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.
    Knösel T; Chen Y; Altendorf-Hofmann A; Danielczok C; Freesmeyer M; Settmacher U; Wurst C; Schulz S; Yang LL; Petersen I
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):397-403. PubMed ID: 22160160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplification of chromosomal segment 4q12 in non-small cell lung cancer.
    Ramos AH; Dutt A; Mermel C; Perner S; Cho J; Lafargue CJ; Johnson LA; Stiedl AC; Tanaka KE; Bass AJ; Barretina J; Weir BA; Beroukhim R; Thomas RK; Minna JD; Chirieac LR; Lindeman NI; Giordano T; Beer DG; Wagner P; Wistuba II; Rubin MA; Meyerson M
    Cancer Biol Ther; 2009 Nov; 8(21):2042-50. PubMed ID: 19755855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
    Szerlip NJ; Pedraza A; Chakravarty D; Azim M; McGuire J; Fang Y; Ozawa T; Holland EC; Huse JT; Jhanwar S; Leversha MA; Mikkelsen T; Brennan CW
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3041-6. PubMed ID: 22323597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma.
    Lassus H; Sihto H; Leminen A; Nordling S; Joensuu H; Nupponen NN; Butzow R
    Br J Cancer; 2004 Dec; 91(12):2048-55. PubMed ID: 15583695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better prognosis of patients with glioma expressing FGF2-dependent PDGFRA irrespective of morphological diagnosis.
    Chen D; Persson A; Sun Y; Salford LG; Nord DG; Englund E; Jiang T; Fan X
    PLoS One; 2013; 8(4):e61556. PubMed ID: 23630597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors.
    Blom T; Roselli A; Häyry V; Tynninen O; Wartiovaara K; Korja M; Nordfors K; Haapasalo H; Nupponen NN
    J Neurooncol; 2010 Apr; 97(2):217-24. PubMed ID: 19779861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling.
    Ruano Y; Mollejo M; Ribalta T; Fiaño C; Camacho FI; Gómez E; de Lope AR; Hernández-Moneo JL; Martínez P; Meléndez B
    Mol Cancer; 2006 Sep; 5():39. PubMed ID: 17002787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone--an array comparative genomic hybridization study.
    Niini T; López-Guerrero JA; Ninomiya S; Guled M; Hattinger CM; Michelacci F; Böhling T; Llombart-Bosch A; Picci P; Serra M; Knuutila S
    Genes Chromosomes Cancer; 2010 Feb; 49(2):132-43. PubMed ID: 19862822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.
    Sihto H; Sarlomo-Rikala M; Tynninen O; Tanner M; Andersson LC; Franssila K; Nupponen NN; Joensuu H
    J Clin Oncol; 2005 Jan; 23(1):49-57. PubMed ID: 15545668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.
    Disel U; Madison R; Abhishek K; Chung JH; Trabucco SE; Matos AO; Frampton GM; Albacker LA; Reddy V; Karadurmus N; Benson A; Webster J; Paydas S; Cabanillas R; Nangia C; Ozturk MA; Millis SZ; Pal SK; Wilky B; Sokol ES; Gay LM; Soman S; Ganesan S; Janeway K; Stephens PJ; Zhu VW; Ou SI; Lovly CM; Gounder M; Schrock AB; Ross JS; Miller VA; Klempner SJ; Ali SM
    Oncologist; 2020 Jan; 25(1):e39-e47. PubMed ID: 31604903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment.
    Zietsch J; Ziegenhagen N; Heppner FL; Reuss D; von Deimling A; Holtkamp N
    PLoS One; 2010 Jul; 5(7):e11858. PubMed ID: 20686603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
    Favero F; McGranahan N; Salm M; Birkbak NJ; Sanborn JZ; Benz SC; Becq J; Peden JF; Kingsbury Z; Grocok RJ; Humphray S; Bentley D; Spencer-Dene B; Gutteridge A; Brada M; Roger S; Dietrich PY; Forshew T; Gerlinger M; Rowan A; Stamp G; Eklund AC; Szallasi Z; Swanton C
    Ann Oncol; 2015 May; 26(5):880-887. PubMed ID: 25732040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.